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Flavonoids were found previously to modulate efficiency of synthesis of glycosaminoglycans (GAGs),
compounds which are accumulated in cells of patients suffering from mucopolysaccharidoses (MPSs). The
aim of this workwas to determine effects of different flavonoids (genistein, kaempferol, daidzein) used alone
or in combinations, on expression of genes coding for proteins involved in GAGmetabolism. Analyses with
DNA microarray, followed by real-time qRT-PCR revealed that genistein, kaempferol and combination of
these two compounds induced dose- and time-dependent remarkable alterations in transcript profiles of
GAGmetabolism genes in cultures of wild-type human dermal fibroblasts (HDFa). Interestingly, effects of
the mixture of genistein and kaempferol were stronger than those revealed by any of these compounds used
alone. Similarly, the most effective reduction in levels of GAG production, in both HDFa and MPS II cells,
was observed in the presence of genistein, keampferol and combination of these compounds. Forty five
genes were chosen for further verification not only inHDFa, but also inMPS II fibroblasts by using real-time
qRT-PCR. Despite effects on GAG metabolism-related genes, we found that genistein, kaempferol and
mixture of these compounds significantly stimulated expression of TFEB.Additionally, a decrease inMTOR
transcript level was observed at these conditions.
M
ucopolysaccharidoses (MPSs) are autosomal, or X-linked (type II) recessive lysosomal storage disorders
caused by the deficiency in activity of a lysosomal enzyme involved in catabolism of glycosaminoglycans
(GAGs)1. Accumulation of GAGs leads to severe clinical symptoms and significantly shortened life span
because of damage of affected tissues and organs, including the heart, respiratory system, bones, joints and, in
most MPS types and subtypes, also central nervous system (CNS).
Over the past two decades, several approaches for the cure of MPS diseases have been proposed, each with a
number of limitations, however2,3. Therapies used in a relatively large fraction of MPS patients, such as cells’
transplantations (CT) and enzyme replacement therapy (ERT), are notably ineffective for neurological symp-
toms, the letter due to the poor distribution of enzyme in the central nervous system (CNS)4. Obstacles to effective
therapies for MPS determine the need for continuous studies in order to enhance therapeutic strategies.
One of such strategies is the implementation of the non-enzymatic substrate reduction therapy (SRT) using
GAG metabolism modulators, such as various flavonoids. We demonstrated previously that natural flavonoids,
such as genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)chromeon-4-on), kaempferol (3,5,7-trihydroxy-2-(4-
hydroxyphenyl)chromen-4-one) and daidzein (7-hydroxy-3-(4-hydroxyphenyl) chromen-4-one) significantly
inhibited synthesis and reduced levels of GAGs in cultures of fibroblasts and in MPSmice5–8. Those results are in
agreement with data published by others, who reported GAG storage correction in cells derived from patients
suffering from either mucopolysaccharidoses type IIIA or VII, after treatment with various isoflavones (a
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subgroup of flavonoids)9. Moreover, combinations of various com-
pounds resulted in more effective reduction of cellular GAG accu-
mulation than the use of any of these flavonoids alone5,9.
As flavonoids can cross the blood-brain barrier, considering them
as compounds potentially useful in the optimization of SRT for neu-
ronopathic forms of MPSs appears reasonable. These compounds are
known to exhibit biological activity through inhibition of various
kinases10, however, the mechanism of action of flavonoids as thera-
peutic agents for MPS treatment remained unclear. Although genis-
tein was believed to inhibit GAG synthesis by blocking the tyrosine
kinase activity of the epidermal growth factor receptor (EGFR)11,
effects of other flavonoids were found to be independent on this
mechanism5. It was demonstrated that, contrary to genistein, other
flavonoids were not effective in inhibiting EGFR phosphorylation5,
however, the exact mechanism of action of flavonoids as genetic
regulators of GAG turnover remains to be elucidated. Recent findings
provided information on a putative genistein targetome responsi-
ble for impairment of synthesis, and more importantly, lysosomal
enhancement of degradation of GAGs by transcription factor EB
(TFEB)12. This may be important in the light of contradictory con-
clusions from different studies regarding effects of genistein on GAG
synthesis and accumulation inMPS andmucolipidosis type II (ML II)
cells, in which either inhibitory8,9,13; or stimulatory14 action of this
isoflavone was reported. On the other hand, one may assume that
elucidation of the mode of other flavonoids’ action on GAG meta-
bolism can be helpful in solving these contradictions completely.
Moreover, understanding the mechanism of correction of cellular
GAG levels by these components and their mixtures may contribute
to potential implementation of them as possible drugs for mucopo-
lysaccharidoses, especially those with neurological symptoms.
Methods
Cell lines, culture media and reagents. Human Dermal Fibroblasts adult (HDFa)
were purchased from the Cascade Biologics (Portland, USA), whileMPS II fibroblasts
were obtained from the Children’s Memorial Health Institute (Warsaw, Poland).
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich,
Steinheim, Germany) supplemented with 10% fetal bovine serum (FBS) and 1%
antibiotic/antimycotic solution (Sigma-Aldrich, Steinheim, Germany) at 37uC in a
humidified atmosphere containing 5% carbon dioxide (CO2). Genistein was
synthetized at the Pharmaceutical Research Institute (Warsaw, Poland), while
kaempferol and daidzein were obtained from Sigma-Aldrich (Steinheim, Germany).
All flavonoids were dissolved in dimethyl sulfoxide (DMSO) and added in the
indicated final concentrations as determined in previous studies5,8 to cell cultures.
Cells were seeded to a confluence of approximately 80% and grown for 24 h. Then,
Figure 1 | Determination of count and viability of HDFa and MPS II cells respectively with 100 mM of genistein, 100 mM of kaempferol, 100 mM of
daidzein, mix of genistein and kaempferol or genistein and daidzein (30 mM each), and with 0.05% DMSO (Ctrl) for different periods of time
(24, 48 and 72 h). Data are represented as mean and bars show SD values of experiments run in triplicate.
Table 1 | Relative levels of GAG synthesis in HDFa and MPS II cells after 72 h treatment with various flavonoids (100 mM genistein, 100 mM
kaempferol, 100 mM daidzein, and mixtures of them of 30 mM each) measured by incorporation of 3H-GlcN. Statistically significant
differences in GAG production levels relative to control cells (treated with DMSO only) are indicated with * for p , 0.005, ** for p ,
0.001, ns – not significant
Flavonoids
3H-GlcN incorporation relative to untreated control cells [%]
HDFa MPS II
Mean value SD Mean value SD
None (DMSO only) 100 7.6 100 9.5
Genistein 54** 8.6 44** 4.6
Kaempferol 35** 2.8 29** 3.2
Daidzein 115* 6.1 97ns 16.2
Genistein 1 Kaempferol 33** 6.9 46** 3.0
Genistein 1 Daidzein 65** 8.5 83* 8.8
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the medium was substituted with either flavonoid-free one, containing DMSO at a
final concentration of 0.05% (control, Ctrl), or the one supplemented with
appropriate amounts of tested flavonoids. Glucosamine, D-[1-3H] hydrochloride
(3H-GlcN) was purchased from Hartmann Analytic GmbH (Braunschweig,
Germany) and Quant-iTTM PicoGreenH dsDNA Reagent was from Life Technologies
(Stockholm, Sweden).
Total RNA extraction. The High Pure RNA Isolation Kit from Roche Applied
Science (Indianapolis, USA) was utilized for total RNA extraction from cells
according to the manufacturer’s instructions. The quality and quantity of each RNA
sample was evaluated using the RNA 6000 Nano Assay on the Agilent 2100
Bioanalyser (Agilent Technologies Inc., USA).
Microarray processing and real-time quantitative RT-PCR assays for mRNA
analysis. Illumina’s Human HT-12v4 Expression BeadChips (Illumina Inc., USA)
were used for the microarray analysis of three biological replicates. The assay
performance, data extraction and statistical analysis were performed as previously
described12. Gene expression data have been deposited in the NCBI’s Gene
Expression Omnibus (GEO, http: www.ncbi.nlm.nih.gov/geo, GEO Series
accession number GSE43692), according to the MIAME standards. Gene
Ontology (GO) tool was used in enrichment analysis together with GOrilla
applied for identification and visualization of enriched GO terms in ranked lists of
genes, and Gene Set Enrichment Analysis (GSEA) for interpreting biological
meaning of defining gene sets15,16.
LightCyclerH System 480 (Roche Applied Science, Indianapolis, USA) was used for
real-time quantitative Reverse Transcription PCR (real-time qRT-PCR) perform-
ance. For cDNA synthesis, 0.5 mg of total RNA was reverse transcribed using the
Transcriptor First Strand cDNA Synthesis kit (Roche Applied Science, Indianapolis,
USA). Real-time qRT-PCR was performed using Real Time ready Custom Panel (cat
no. 05532914001, config. no. 90014731, Roche Applied Science, Indianapolis, USA)
and LightCyclerH 480 Probes Master (Roche Applied Science, Indianapolis, USA)
according to the manufacturer’s instructions.
For both, microarray and real-time qRT-PCR analyses, a fold change (FC) greater
or equal to 2.0 or 1.3, and below 0.5 or 0.7, for whole genome or GAG associated
transcripts, respectively, was considered as a relevant criterion for genes being
significantly differentially expressed.
Statistical analyses of microarray and qRT-PCR data. Each experiment of
microarray as well as real-time qRT-PCR analyses was repeated at least three times
(n). Data are reported as the mean 6 SD with p , 0.05 considered statistically
significant. Statistical analysis of TFEB expression made via real-time qRT-PCR was
performed using ANOVA with Tukey’s HSD Post Hoc test with p , 0.005.
Cell number and viability assessment. HDFa and MPS II fibroblasts’ cells were
seeded in triplicate in 6-well plates at a density of 104 per well. The medium was
changed the following day and supplemented with appropriate amounts of tested
flavonoids, or 0.05%DMSO as control, for 24, 48 or 72 hours. Cells were counted and
viability was estimated by MUSEH Cell Analyzer (Merck Millipore, Germany) and
MuseHCount & Viability Assay Kit (MerckMillipore, Germany). An average of 2000
cells was analyzed for each condition.
Measurement of kinetics of GAG synthesis. Kinetics of GAG was estimated by
measurement of incorporation of glucosamine, D-[1-3H] into GAG chains. In brief,
cells were plated in a number of 2 3 104 per well in 48-well plate and incubated
overnight to allow the attachment. Next, cells were preincubated for 48 hours in
standard DMEM supplemented with appropriate amounts of flavonoids or DMSO
(control cultures) and then cells were labelled for 24 hours with 10 mCi/ml of 3H-
GlcN in DMEM without glucose and pyruvate supplemented with 10% FBS and
flavonoids or DMSO. After labelling, cells were washed six times with PBS and
digested for 3 hours at 65uCwith 0.5% papain (prepared in 200 mMphosphate buffer
(Na2HPO4 - NaH2PO4), pH 6.4, containing 100 mM sodium acetate, 10 mM
Na2EDTA and 5 mM L-cysteine). Incorporation of 3H-GlcN was measured in
MicroBeta2 scintillation counter [PerkinElmer] andQuant-iTTM PicoGreenH dsDNA
Reagent was used to determine DNA concentration in papain digested samples.
Incorporation of 3H-GlcN was calculated per DNA amount (cpm/ng of DNA) and
expressed as relative to control cultures (treated with DMSO alone). To test the
efficiency of flavonoids on kinetics of GAG synthesis, one-way ANOVA was
performed with Tukey’s multiple comparisons test as a post-hoc comparator with
significance declared at p , 0.05.
Assessment of GAG levels. Accumulation of GAGs was estimated with Alcian Blue
reagent using sGAG quantitative kit WIESLABH. In brief, confluent cells were plated
in a number of 1.5 3 105 per well in 6-well plate and incubated overnight to allow the
attachment. Next, cells were supplemented with standard DMEM with appropriate
amounts of flavonoids orDMSO (control cultures). Themediumwas replaced every 5
days. After 10-days of incubation harvested cells were digested with 0.5% papain (see
GAG kinetics experiment) and GAG content with Alcian Blue and DNA
concentration with PicoGreen were estimated according tomanufacturer’s protocols.
GAG content was per DNA amount (mg/mg of DNA) and normalized to control
cultures (treated with DMSO alone). T
ab
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Results
Selection of flavonoids and their cytotoxic activity. It has been
demonstrated previously that genistein (an isoflavone), kaempferol
(a flavonol) and daidzein (an isoflavone) are among flavonoids which
inhibit GAG synthesis considerably in cultured MPS fibroblasts,
permitting significant reduction in lysosomal storage5,8,9. Moreover,
mixtures of those compounds, i.e. genistein plus kaempferol, and
genistein plus daidzein, resulted in even more effective reduction of
GAG accumulation than the use of any of these flavonoids alone5.
Apart from genistein, previously investigated in the context of
lysosomal modulation12, in this study, the above mentioned two
compounds, as well as their mixtures, were selected and applied for
further transcriptomic network analysis.
To examine the cytotoxicity effect of selected flavonoids and mix-
tures of those compounds wemeasured viability of HDFa andMPS II
fibroblasts treated with 100 mM of genistein, 100 mM of kaempferol,
100 mM of daidzein, mix of genistein and kaempferol or genistein
and daidzein (30 mM each), and with 0.05% DMSO (control) for
different periods of time (24, 48 and 78 h). As seen in Figure 1 the
cell viability did not change remarkably at the tested conditions.
Effects of flavonoids and their mixtures on GAG synthesis and
storage. Because literature contains publications reporting either
inhibition of GAG synthesis and resultant decreased storage5,8,9,13,17
or opposite results14 in different cells, we tested effects of flavonoids
andmixtures of them in cultures of both HDFa andMPS II fibroblasts.
Tested compounds were added individually, i.e. genistein, kaempferol,
daidzein at the final concentration of 100 mM, or applied as mix of
them, i.e. genistein and kaempferol or genistein and daidzein (30 mM
each) to cell cultures. Synthesis of GAGs was measured by estimation
of the amount of incorporated precursor, glucosamine, D-[1-3H]
hydrochloride. We found that all tested flavonoids, except for
daidzein, inhibited GAG synthesis significantly in both wild-type
and MPS cells (Table 1). The most pronounced impairment of
production of GAG was observed in the presence of genistein,
keampferol and mixture of these two, relatively to untreated control
cells. Therefore, we confirmed inhibitory effects of genistein and
keampferol on GAG synthesis in the cells employed in this study.
Effects of flavonoids on GAG storage was measured after 10 days
of treatment as changes in GAG levels are slower than effects on
synthesis of these compounds. Moreover, recent studies indicated
Figure 2 | Distribution of up- (red) and down-regulated (blue) transcripts of whole genome of HDFa cells after 24 and 48 h treatment with (A)
genistein (100 mM), (B) kaempferol (100 mM), (C)mix of genistein and keampferol (30 mMeach), (D) daidzein (100 mM), and (E)mix of genistein and
daidzein (30 mM each), at 0.5 $ FC $ 2 for n $ 3, with the p-value , 0.05. DMSO-treated cells were used in control experiments.
www.nature.com/scientificreports
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that GAG levels could be modulated by genistein due to stimulation
of lysosomal biogenesis12. We found a decrease in GAG levels in cells
treated with all tested flavonoids, including daidzein which did not
decrease GAG synthesis (Table S1). Thus, we conclude that these
compounds decrease storage in employed cells, due to inhibition of
GAG synthesis or stimulation of lysosomal biogenesis or both.
Microarray data association. An overview of microarray experiment
performance was gained by clustering samples using correlationmetric
(IlluminaH BeadStudio Data Analysis Software). A comparison of dif-
ferentially treated samples in the global gene expression pattern was
performed for all the biological repeats individually as well as together,
based on the correlation distance between all samples computed with
the Pearson Correlation Coefficient (PCC). We used hierarchical clus-
tering with average linkage as agglomeration rule (data not shown).
Dendrograms based on this metric are useful for identifying outliers, as
samples with most similar expression profiles determined by correla-
tion value are clustered together. The hierarchical agglomerative clus-
tering identified two main groups, one including group treated for
24 h, and the other treated for 48 h, all containing three replicates.
Each group was composed of cells divided into eight subgroups,
which are cells treated with kaempferol at concentrations of 30, 60
or 100 mM, with mix of genistein and kaempferol (30 mM each), with
daidzein at 60 or 100 mM, with mix of genistein and daidzein (30 mM
each), with 0.05% DMSO, and DMSO-treated cells (non-treated con-
trol). Next, the reproducibility between replicate samples was assessed
also by calculating PCC. The values ranging between 0.97 and 0.99 for
biological replicates show a high degree of reproducibility and strong
correspondences between expression profiles. These associations may,
in the global view, indicate a prevalence of cells with respect to certain
treatment effect on gene expression profiles.
Effects of flavonoids on global gene expression.Microarray analyses
were performed on HDFa cells after 24 and 48 h of either vehicle or
30, 60, or 100 mM compound treatment, or their mixtures, 30 mM
each. The detailed studies revealed that the cells responded to different
types of treatment with changes in gene expression profiles, affect-
ing large number of genes that showed changes greater than 2-fold
(Table 2). Concentration- and time-dependent effects of tested flavo-
noids on global gene expression in fibroblasts were observed. The
highest number of genes with modulated expression was observed
for kaempferol and genistein-kaempferol mix treatment type of fibro-
blasts after both 24 and 48 hours. In total, 698 and 362 for 24 h, and
1506 and 1328 transcripts for 48 h handling with 100 mM kaempferol
and mix of genistein with kaempferol (30 mM each), respectively, were
Figure 3 | Genes identified as changed under studied conditions with
corresponding overlap between the datasets (0.5 $ FC $ 2, n $ 3, with
the p-value , 0.05). Up- and down-regulated genes of whole genome of
HDFa cells after 24 and 48 h treatment with 100 mM genistein, 100 mM
kaempferol, genistein-kaempferol of 30 mM each, 100 mM daidzein and
genistein-daidzein of 30 mM each.
Figure 4 | Number of genes whose expression was altered as a function of the FC in response to various flavonoids’ treatment type (100 mM genistein,
100 mM kaempferol, 100 mM daidzein, and mixtures of them of 30 mM each), identified in the microarray analysis of whole genome sequences
and transcripts of HDFa cells (n $ 3, with the p-value , 0.05).
www.nature.com/scientificreports
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Figure 5 | Genes with significantly (i.e. more than 10-fold change) regulated expression upon various flavonoids’ treatment (100 mMgenistein - GEN,
100 mM kaempferol - KAEM, 100 mM daidzein - DAIDZ, and mixtures of them of 30 mM each, GEN1 KAEM or GEN1 DAIDZ) identified in the
microarray analysis of whole genome sequences and transcripts of HDFa cells (n $ 3, with the p-value , 0.05).
Table 3 | GAG metabolism genes of HDFa after 24 and 48 h treatment with various flavonoids (100 mM genistein, 100 mM kaempferol,
100 mM daidzein, and mixtures of them of 30 mM each) identified in the microarray analysis (0.7$ FC$1.3, n$3, with the p-value,
0.05). Cells shaded in red stand for up-regulation, while in blue for down-regulation
GAG metabolism Genes
Compounds
Genistein1) Kaempferol Genistein 1 Kaempferol Daidzein Genistein 1 Daidzein
Time of exposure [h]
24 48 24 48 24 48 24 48 24 48
GAG synthesis Chain initiation B3GAT3
B4GALT7
XYLT1
Chain polymerization B3GNT2
B4GALT1
B4GALT4
CHPF
CHSY3
CSGALNACT2
EXT1
EXT2
EXTL2
EXTL3
ST3GAL1
ST3GAL2
ST3GAL3
Chain modification CHST12
CHST14
CHST2
CHST3
CHST7
GLCE
HS2ST1
HS3ST3A1
NDST1
UST
GAG degradation GALNS
GNS
GUSB
HEXA
HEXB
HYAL3
IDUA
NAGLU
SGSH
1)Results based on raw data from Moskot et al. (2014).
www.nature.com/scientificreports
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affected. Moreover, number of genes exhibiting regulated activity,
including both increased and decreased expression, was considerably
higher for kaempferol and genistein-kaempferol treated cells than
in case of those exposed to genistein alone, as reported by Moskot
et al. (2014). In the course of this study, we obtained 436 (100 mM
kaempferol), 242 (genistein and kaempferol, 30 mM each), 41
(100 mM daidzein) and 24 (genistein and daidzein, 30 mM each)
transcripts, which levels were affected after both 24 and 48 hour
treatment time period (Figure 2), while 263 for 100 mM genistein
handling of cells as previously described12. Among 4 genes that
displaced a greater than 2-fold increase in expression after 24 and
48 h at 100 mM kaempferol, genistein-kaempferol of 30 mM each,
100 mM daidzein and genistein-daidzein of 30 mM each, MAOA
was the only transcript modulated also at 100 mM genistein as
reported earlier12, while KRT34 was the only gene down-regulated
at all these conditions (Figure 3). MAOA and KRT34 are related to
complications associated with various lysosomal storage disease such
as mucopolysaccharidoses12,18–20.
Furthermore, detailed analysis showed a significant, i.e. higher
than 10-fold, enhancement of gene expression, mainly in kaempferol
and genistein-kaempferol treated cells (Figure 4), for SLC40A1
mRNA species, up-regulated for both the 24 and 48 hour exposures,
and SLC40A1 and IL6 transcripts, enriched only after 48 hour time
course set (Figure 5).
Activity of genes involved in GAG metabolism pathways and
lysosomal function. It was possible to produce a refined list of genes
involved in GAG metabolism that were consistently differenti-
ally expressed in HDFa cells treated with various flavonoids and
mixtures of them (Table 3). Within this list, there are several genes
that were activated by more than one treatment conditions, however,
among them only 2 genes, EXT1 and HS3ST3A1, associated with the
GAG synthesis pathway, were down-regulated at all tested flavonoids
after 24 and 48 hours, respectively. Among genes involved in GAG
degradation,GNS andHEXAwere up-regulated after kaempferol and
kaempferol-genistein treatment for 48 h. In general, handling of
cells with 100 mM kaempferol for 48 h affected the highest number
of genes involved in GAGmetabolism pathways (i.e. 13 genes of GAG
biosynthesis and 7 of GAG degradation) (Table 3).
Our analyses identified also dozens of genes with known roles in
lysosomal biogenesis and/or function, which expression was altered
by tested flavonoids (partly included in Table 4). These data are in
substantial correlation with results reported previously, where it was
found that genistein remarkably stimulated genes encoding lyso-
somal proteins12. Furthermore, detailed studies revealed 3 genes
(CLN5 coding for ceroid-lipofuscinosis neuronal protein 5 pre-
cursor, LGMN coding for legumain and MANBA coding for beta
mannosidase, all up-regulated after 24 and 48 h) with modulated
activity at all tested flavonoids (data not shown).
Real-time quantitative RT-PCR for mRNA analysis of GAG
metabolism- and lysosome- associated genes. We used a real-time
quantitative RT-PCR approach to examine in more detail the expres-
sion patterns of genes involved in GAG metabolism, as well as in
lysosome biogenesis and function, whose activities were modulated
in fibroblasts at tested conditions, as observed in microarray studies.
Real Time ready Custom Panel covering in total 45 genes, 13 of GAG
metabolism pathways (7 of GAG synthesis and 6 of GAG degra-
dation) and 30 sequences coding for lysosomal proteins, all reveal-
ing modulated activity in microarray analysis, was designed. The
expression of genes was confirmed not only in HDFa cells, but also
in MPS II fibroblasts, after 24 h treatment (Table 4), as well as at 48 h
period (data not shown), with respect to TRFC (transferrin receptor
gene), the reference of constant expression level. The same pattern
of mRNA level of all verified genes was observed when two other
reference genes, PGK1 and RPLPO, were considered (data not shown).
In general, the two independent gene expression profiling methods
showed a strong correlation, as for each, similar patterns of expression
were observed whether using the microarray or real-time qRT-PCR
analysis (Table 4). Similarly to previously published results obtained
with genistein-treated cells12, here we report that among genes with
significantly altered activity in the presence of kaempferol and mixture
of genistein-kaempferol, in both HDFa and MPS II fibroblasts treated
for 24 h, there are those participating in GAG metabolism pathways
(i.e. EXT1, HS3ST3A1 and XYLT1 involved in anabolism, and HEXA
in catabolism of GAG). This impact is, however, less pronounced than
that reported previously for genistein12. Moreover, we confirmed con-
siderable up-regulation of expression of several lysosome-associated
genes (i.e. ACP5, AGA, AP3S2, ARSG, CLN3, CLN5, CTSF, LGMN,
MAN2B1, MANBA, NEU1, NPC1 and SUMF1) in response to tested
flavonoids after 24 h period of their action (Table 4).
TFEB andMTOR transcript amount assessment. Interestingly, we
found that the tested flavonoids induced an increase in TFEBmRNA
Figure 6 | TFEB andMTOR expression analysis in HDFa andMPS cells via real-time qRT-PCR.Data represent averaged values 6 SD from n 5 3, and
mean significant differences for samples treated for 24 h with various flavonoids (100 mMgenistein, 100 mMkaempferol, andmixtures of them of 30 mM
each) against non-treated, with respect to endogenous reference gene GAPDH (in HDFa) and RPLPO (in MPS II), with p , 0.005 as determined by
ANOVA with Tukey’s HSD Post Hoc.
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level and a decrease in MTOR (gene coding for Serine/Threonine-
Protein Kinase MTOR) transcript amount compared with the
untreated samples, in both HDFa and MPS II cells treated for 24 h
(Figure 6), in respect to GAPDH and RPLPO, correspondingly.
Qualitatively similar results were obtained for other two reference
genes, TBP in HDFa, andTFRC inMPS II fibroblasts (data not shown).
Gene Ontology and Gene Set Enrichment analyses. By selecting
informative genes from microarray data via Gene Ontology analysis,
we found that all tested conditions altered the expression of genes
belonging to a wide range of pathways involved in ‘Cellular Compart-
ment’ organization and ‘Biological processes’ (Figure 7). Network
related to lysosome biogenesis and/or function was basically identified
for ‘Cellular Compartment’ terms analysis only when samples were
treated with mixture of genistein-kaempferol, as well as with kaemp-
ferol alone. These enrichments were, however, noticeably weaker than
those observed when genistein was applied12. Accordingly, Gene Set
Enrichment Analysis showed a significant enrichment among these
lysosome-associated genes regulated by genistein-kaempferol mix and
kaempferol (Table 5), with normalized Enrichment Score (Figure 8),
again still weaker than in the case of genistein, as reported previously12.
Discussion
Although all types of mucopolysaccharidoses, inherited metabolic
diseases characterized by lysosomal storage of GAGs, are caused by
mutations in single genes, their pathomechanisms are more compli-
cated than just accumulation of non-degradable compounds in cells.
Although the storage is the primary effect of each MPS-causing
mutation, there are various secondary and tertiary effects that lead
to a complicated picture of eachMPS type and subtype, as well as to a
high variability of symptoms among patients suffering from the same
disease (for a recent review, see21). In the light of this complicated
pathomechanism of the disease, it appears crucial to precisely under-
stand mechanisms of actions and effects of any potential drugs that
could be used in MPS treatment. One group of such potential drugs
are flavonoids, compounds which were reported previously to par-
tially inhibit GAG synthesis and to reduce GAG storage in cells
derived from MPS patients. Among them, genistein (an isoflavone)
has been studied intensively, and it was proposed that this compound
can down regulate GAG production by blocking phosphorylation of
the EGF receptor, thus, impairing a signal transduction pathway
necessary for activation of genes coding for enzymes involved in this
anabolic process8,11. Nevertheless, other studies indicated that differ-
ent flavonoids, either natural or synthetic, can also significantly
modulate GAG synthesis and storage, while acting through an
EGF-independent mode5,9,17. Enhanced effects of combinations of
various flavonoids on GAG synthesis and accumulation, relative
to single compounds from this group, have also been reported5,9.
Furthermore, recent studies indicated that, at least under certain
conditions, genistein might stimulate, rather than inhibit, synthesis
of GAGs14, which was in contrast to previous reports showing
impairment in GAG production and storage in MPS and ML II cells
treated with this isoflavone8,9,13. Results of very recent studies led to
conclusions that genistein can both inhibit expression of some genes
coding for GAG-synthesizing enzymes and stimulate expression of
most of genes which products are involved in GAG degradation; the
latter effect appears to be due to activation of expression of TFEB, a
gene coding for transcription factor EB, and transport of this protein
into nucleus12.
In the light of the above described facts and uncertainness on
mechanisms of flavonoid-mediated regulation of GAG metabolism,
in this work, the transcriptome of the cell line HDFa was profiled
with Illumina’s HumanHT-12 v4 Expression BeadChips in the pres-
ence or absence of various flavonoids or their mixtures. Results of the
microarray analyses provided preliminary pictures of influences of
tested compounds on cell transcriptome. However, since simultan-
eous analysis of thousands of genes may potentially lead to either
false positive or false negative results, we have repeated analysis of
selected genes, which signals in the microarray experiments sug-
gested a significant influence of tested compounds on their express-
ion, by using real-time qRT-PCR. The latter method allows for
precise determination of the level of particular transcript, in a quant-
itative manner. The real-time qRT-PCR experiments involved not
only HDFa cells, but also fibroblasts derived from a patient suffering
from MPS II.
Transcriptome analyses indicated that, despite certain similarities,
there are also significant differences between effects of genistein,
kaempferol, and daidzein on global gene expression patterns in
human wild-type fibroblasts. The results suggested that these flavo-
noids may differentially influence GAG metabolism, indeed. This
was confirmed by real-time qRT-PCR studies, in which genes coding
for proteins involved in GAG synthesis and degradation were inves-
tigated in more detail. Importantly, both microarray and real-time
qRT-PCR analyses gave similar results, indicating accuracy of both
methods. Moreover, changes in expressions of these genes in flavo-
noid-treated cells, relative to controls, were similar in both wild-type
and MPS II fibroblasts. Therefore, we conclude that GAG storage
does not influence significantly the response of tested genes to
Table 5 | GSEA analysis of selective gene sets enriched among genes up-and down-regulated by tested flavonoids (100 mM genistein,
100 mM kaempferol, 100 mM daidzein, and mixtures of them of 30 mM each, for 24 and 48 hours) in HDFa cells
Enrichment
Genistein Kaempferol Genistein 1 Kaempferol Daidzein Genistein 1 Daidzein
Time of exposure [h]
24 48 24 48 24 48 24 48 24 48
Up-regulation Gene sets significant in phenotype 73 73 86 71 80 109 115 86 95 99
Gene sets significant at FDR , 25% 38 22 33 9 35 35 7 14 13 24
Gene sets significantly enriched
at nominal p-value , 1%
13 8 15 5 15 16 4 5 6 14
Down-regulation Gene sets significant in phenotype 105 105 92 107 98 69 63 92 83 79
Gene sets significant at FDR , 25% 54 48 27 56 24 15 0 13 1 4
Gene sets significantly enriched
at nominal p-value , 1%
31 31 13 29 14 14 0 9 4 5
Figure 7 | GO analysis by ‘Cellular Compartment’ (A) and ‘Biological Processes’ (B) category of the genes with up-regulated expression upon various
flavonoids’ treatment (100 mM genistein, 100 mM kaempferol, and mixtures of them of 30 mM each, for 24 and 48 hours) of HDFa cells, with
false discovery rate (FDR) , 0.1, fold change $ 1.3 and below 0.7, and p , 0.001.
www.nature.com/scientificreports
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Figure 8 | Graphs showing the enrichment plots generated by GSEA analysis of ranked gene expression data (UP: up-regulated, red; DOWN: down-
regulated, blue). Sizes of normalized enrichment score (NES), q-value of false discovery rate (FDR q-val), and nominal p-value (NOM p-val) for
lysosome-associated gene sets regulated by tested flavonoids (100 mM genistein, 100 mM kaempferol, and mixtures of them of 30 mM each, for 24 and
48 hours) in fibroblasts are depicted. The enrichment score is shown as a scattered green line, and the horizontal black bars next to the plot indicate the
position of lysosome-associated genes, which are mostly grouped in the fraction of up-regulated genes.
www.nature.com/scientificreports
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investigated compounds. Interestingly, effects of genistein (an iso-
flavone) were more similar to those of keampferol (a flavonol) than
daidzein (another isoflavone). In fact, daidzein differs from genistein
only by a lack of one hydroxyl group, suggesting that this moiety may
be crucial in functions of flavonoids as regulators of expression of
genes involved in GAG metabolism. This can be assumed on the
basis of significantly less pronounced effects of daidzein relative to
other flavonoids (Table 1 and 3). On the other hand, despite obvious
overlaps, there are also differences in genes which expression is either
stimulated or impaired by genistein and kaempferol. Intriguingly,
the differences could be observed mostly in expression of genes cod-
ing for enzymes involved in GAG synthesis. This might corroborate
previous suggestions5,17 that detailed mechanisms of regulation of
these genes by various flavonoids may be different. Most probably
different signal transduction pathways are differentially affected by
genistein, kaempferol and daidzein, which results in specific tran-
scription patterns of GAG metabolism-related genes in cells treated
with these compounds. This hypothesis is supported by earlier find-
ings that genistein, but not kaempferol and daidzein, inhibits phos-
phorylation of EGF receptor5,11.
Contrary to genes coding for GAG-synthesizing enzymes, effects of
genistein and kaempferol on expression of genes encoding enzymes
responsible for GAG degradation were similar. In both cases, tran-
scription of most such genes was stimulated. Daidzein was inactive in
this mechanism, as no increase in the level of any GAG degradation-
related gene transcript could be detected. Again, a difference in a single
chemical moiety results in dramatically different effects of particu-
lar flavonoid on expression of genes controlling GAG degradation
(Table 3). On the other hand, it is likely that stimulation of expression
of these genes by genistein and kaempferol is due to modulation of the
same process. Both these flavonoids enhance expression of the gene
coding for TFEB (Figure 6), a master regulator for lysosomal biogen-
esis and function22–24, and impair expression of the gene encoding
MTOR (Figure 6), a serine/threonine-protein kinase that phosphor-
ylates TFEB, preventing its entering into the nucleus25–28. Interestingly,
a combination of genistein and kaempferol did not cause an increase
in their effects on TFEB and MTOR expression. This is in contrast to
previously reported synergistic effects of isoflavones and or other
flavonoids on GAG synthesis inhibition5,9,17. We conclude that among
two mechanisms of modulation of GAG metabolism by flavonoids,
the inhibition of GAG synthesis is regulated by various pathways,
depending on the kind of flavonoid, which may result in a cumulative
effect if mixtures of two or more active compounds are used, as
reported previously. In contrast, stimulation of lysosomal biogenesis
(including enhancement of expression of genes coding for GAG-
degrading enzymes) by different flavonoids (providing they are active
in this process) may proceed according to the same mechanism, based
on modulation of TFEB and MTOR levels. Therefore, combination of
two flavonoids does not result in a synergistic effect in this regulatory
pathway.
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